CurrentBlue Cross Blue Shield - LouisianaPolicy 00957

Prostate Artery Embolization (PAE) for Benign Prostatic Hyperplasia

This policy governs coverage for prostate artery embolization as a treatment for benign prostatic hyperplasia (BPH) for products administered or underwritten by Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc.

Policy Summary

PayerBlue Cross Blue Shield - Louisiana

PolicyProstate Artery Embolization (PAE) for Benign Prostatic Hyperplasia

Policy CodePolicy 00957

Change TypeNo material changes

Effective Date06/01/2026

Next Review Date

Key ActionDo not authorize prostate artery embolization because it is considered investigational and not covered.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7RCTs in Cochrane

3Recent RCTs

317Retrospective study size

1CPT codes listed

2ICD-10 codes listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered — Investigational

Coverage determination

Investigational determination: Prostate artery embolization is considered investigational for treatment of benign prostatic hyperplasia

Investigational services are not covered by the Company

Investigational or experimental services are not covered by the Company. This exclusion applies to any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. Prostate artery embolization (PAE) for benign prostatic hyperplasia (BPH) is considered investigational and coverage is not available.

Medical policies are scientific, evidence-based opinions intended to guide coverage decisions. When a member’s health insurance contract contains language that differs from this Medical Policy, the contract language governs. In addition, federal and state law and specific contract provisions/exclusions take precedence over the Medical Policy and must be considered first when determining eligibility for coverage.

Because PAE is designated investigational based on the available evidence review, it is excluded from coverage and authorizations for this service will not be approved. Coverage is not available for investigational treatments or procedures, including prostate artery embolization for BPH.

Provider Requirements and Impact

Denial Risk

PAE Considered Investigational — Not Covered

Prostatic artery embolization (PAE) is designated investigational and is not a covered service. Prior authorization does not make an investigational service covered; authorization requests for PAE will be denied as investigational.

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc.
Investigational or experimental services are excluded from coverage regardless of prior authorization status
Transurethral water vapor (Rezum), water jet ablation (Aquablation), prostatic urethral lift, and iTind are addressed in separate policies (00480, 00684, 00825)

Prior Authorization

Prior Authorization May Apply for CPT 37243

Certain related procedure codes (for example, embolization procedures such as CPT 37243) may require prior authorization per plan administrative rules. Providers should verify benefit-specific prior authorization requirements before scheduling.

CPT 37243 may be subject to prior authorization per plan
Prior authorization requirements vary by member contract — check eligibility and benefits

Note

Typical Treatment Pathway for BPH

Typical management of benign prostatic hyperplasia (BPH) includes watchful waiting, pharmacotherapy, and a range of minimally invasive surgical procedures; PAE is not part of the medically accepted treatment pathway per this policy.

Conservative options: watchful waiting and medical therapy
Minimally invasive options and surgical treatments (e.g., TURP) are covered per separate policies when medically indicated

Documentation Required

Transition Authorization Documentation

Providers should be aware that authorizations issued by a prior carrier for an ongoing course of treatment may be honored for a 90-day transition period if documentation is provided and the service is otherwise covered under the Louisiana Blue plan. This transition provision does not apply to pharmacy benefits.

Documentation of prior authorization must be provided by the member or provider
Transition applies only when the service is a covered benefit under the new plan
Does not apply to medications under the pharmacy benefit

Denial Risk

Investigational Designation Triggers Denial

Services designated investigational will be denied. Federal/state law and specific contract provisions take precedence over this medical policy; verify member contract language for coverage determination.

Investigational designation triggers denial of coverage
If the member’s contract differs from this policy, the contract governs coverage determinations
Providers may receive denials for services that are investigational or that do not meet policy criteria

Clinical Background

Benign prostatic hyperplasia (BPH) is a common, nonmalignant enlargement of the prostate that occurs with aging and may cause lower urinary tract symptoms (LUTS) such as urinary frequency, urgency, nocturia, weak stream, and incomplete bladder emptying. These symptoms can substantially affect health-related quality of life and functional status. Traditional surgical management such as transurethral resection of the prostate (TURP) has been the historical reference standard, while a range of medical therapies and minimally invasive procedures (including emerging endovascular approaches like PAE) have been studied as alternatives with varying mechanisms, risks, and recovery profiles.

Definitions

Prostate arterial embolization (PAE)

DefinitionProstate arterial embolization (PAE) is a minimally invasive endovascular procedure in which an interventional radiologist injects microspheres through a catheter into prostatic arteries to reduce blood supply to the prostate.

MechanismEmbolic reduction of prostatic blood flow targeting multiple prostatic arterial branches to shrink prostate tissue and relieve LUTS.

Procedure setting and recoveryNo transurethral surgical incision is required; recovery times are often shorter than transurethral resection of the prostate (TURP).

PractitionerPerformed by an interventional radiologist trained in endovascular embolization techniques.

Common adverse effectsCan include post-PAE syndrome, hematuria or hematospermia, and rare prostatic or bladder spasms.

Benign prostatic hyperplasia (BPH)

DefinitionBenign prostatic hyperplasia (BPH) is a histologic diagnosis characterized by an increase in stromal and glandular epithelial cells within the transition zone of the prostate, which may lead to prostate enlargement and lower urinary tract symptoms (LUTS).

Common symptomsUrinary frequency, urgency, weak stream, irregular flow, straining, and nocturia that can impact quality of life.

EpidemiologyAffects a substantial proportion of older men (approximately 40% in their 50s, 70% in those 60–69, and ~80% in men 70+).

Treatment considerationsManagement ranges from watchful waiting and medications to minimally invasive or surgical procedures; TURP is the traditional reference standard.

Investigational (policy definition)

Investigational definitionA medical treatment, procedure, drug, device, or biological product is Investigational if its effectiveness has not been clearly tested and it has not been incorporated into standard medical practice.

Implication for coverageServices designated Investigational are not covered under this policy (investigational or experimental services are excluded).

Basis for determinationDeterminations are based on consideration of available evidence regarding effectiveness and incorporation into standard practice.

Policy applicationIncludes procedures provided under the investigational arm of a clinical trial or clinical study as excluded from coverage unless otherwise specified by contract or law.

N40.0	Enlarged prostate without lower urinary tract symptoms
N40.01	Benign prostatic hyperplasia with lower urinary tract symptoms

OpenPayer

Prostate Artery Embolization (PAE) for Benign Prostatic Hyperplasia

Coverage Determination

Coding and Billing

Provider Requirements and Impact

Clinical Background

Definitions